Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT05860699
PHASE2

Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation : CBD-OH

Sponsor: Assistance Publique - Hôpitaux de Paris

View on ClinicalTrials.gov

Summary

Randomized clinical trial of 11 days Cannabidiol versus placebo as an adjunctive treatment during inpatient alcohol detoxification to improve abstinence in patients with severe alcohol use disorder.

Official title: Cannabidiol as an add-on Treatment During Inpatient Alcohol Cessation in Patients With Severe Alcohol Use Disorder: A Phase II Trial

Key Details

Gender

All

Age Range

18 Years - 75 Years

Study Type

INTERVENTIONAL

Enrollment

210

Start Date

2024-04-08

Completion Date

2026-05-23

Last Updated

2025-12-03

Healthy Volunteers

No

Interventions

DRUG

Placebo

Placebo made by the same manufacturer to look like the active pills

DRUG

Half dose CBD

add-on cannabidiol (Echo Pharmaceutical, BV) 450 mg per day for 11 days during their inpatient stay

DRUG

Full dose CBD

add-on cannabidiol (Echo Pharmaceutical, BV) 900 mg per day for 11 days during their inpatient stay

Locations (12)

Hôpital Albert Chenevier

Créteil, Albert Chenevier, France

Hôpital Antoine Béclère

Clamart, Clamart, France

CHU Gabriel Montpied

Clermont-Ferrand, Clermont Ferrand, France

Hôpital Louis Mourier

Colombes, Colombes, France

Hôpital Avicenne

Bobigny, France, France

Hôpital Fernand Widal

Paris, France, France

Hôpital Hôtel-Dieu

Paris, Paris, France

Hôpital Cochin

Paris, Paris, France

Hôpital Saint Anne

Paris, Paris, France

Hôpital Bichat

Paris, Paris, France

Hôpital René Muret

Sevran, Sevran, France

Hôpital la Colombière

Montpellier, France